SCHEMBL2477333

SCHEMBL2477333

CC(C)(C)OC(=O)Nc1ccccc1NC(=O)c1ccc(C(CCCN2CCOCC2)NC(=O)Nc2nc3c(s2)CCCC3)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR1 Q9BXC0 1/20 0.39
CD274 Q9NZQ7 1/20 0.39
RAB9A P51151 5/20 0.39
SMN1; SMN2 Q16637 5/20 0.39
LMNA P02545 5/20 0.39
MAPT P10636 4/20 0.39
NPC1 O15118 4/20 0.39
GFER P55789 2/20 0.39
CLK1 P49759 1/20 0.39
ALDH1A1 P00352 5/20 0.38
ROCK2 O75116 3/20 0.38
KDM4E B2RXH2 3/20 0.38
GAA P10253 2/20 0.38
MEN1 O00255 2/20 0.38
TP53 P04637 2/20 0.38
KMT2A Q03164 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
HPGD P15428 1/20 0.38
MAPK1 P28482 1/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4401245 0.88 HDAC1 (0.45) RAB9ASMN1; SMN2LMNAMAPTNPC1
SCHEMBL2477400 0.84 CYP2D6 (0.48) CD274RAB9ASMN1; SMN2LMNANPC1
SCHEMBL3832883 0.82 MEN1 (0.39) CD274RAB9ASMN1; SMN2LMNAMAPT
SCHEMBL4399525 0.82 OPRM1 (0.41) HCAR1CD274RAB9ASMN1; SMN2LMNA
SCHEMBL2477762 0.82 CD274 (0.45) CD274RAB9AMAPTALDH1A1KDM4E
SCHEMBL2474232 0.81 NAMPT (0.47) CD274RAB9ASMN1; SMN2LMNANPC1
SCHEMBL2477110 0.80 KDM1A (0.47) CD274RAB9ALMNAMAPTNPC1
SCHEMBL2476095 0.79 CD274 (0.47) CD274SMN1; SMN2ALDH1A1KDM4EGAA
SCHEMBL2477555 0.79 CD274 (0.47) CD274LMNAMAPTALDH1A1KDM4E
SCHEMBL2474155 0.79 CD274 (0.42) CD274RAB9ANPC1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
EP-2107052-B1 NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE SANTEN PHARMACEUTICAL CO LTD (JP) 2011-10-12 EP disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
EP-2107052-A1 NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE Santen Pharmaceutical Co., Ltd (JP) 2009-10-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE UACA, SLC14A1, ARG2 HCAR1 2007/4885CD274 4808/4885RAB9A 1942/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.